% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • gosmokeadoobie gosmokeadoobie Mar 26, 2013 8:58 PM Flag

    Imetelstat in Treating Young Patients With Lymphoma

    Children's Oncology Group
    National Cancer Institute (NCI)

    A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas

    Estimated Enrollment: 45
    Study Start Date: May 2011
    Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)

    Primary Outcome Measures:

    Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma [ Designated as safety issue: Yes ]
    Toxicities of imetelstat sodium [ Designated as safety issue: Yes ]

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.47-0.12(-4.63%)11:29 AMEDT